Six abstracts; including new phase 2 data for nemolizumab across PN and AD and new real-world evidence highlighting the PN disease burden being presented
Prurigo nodularis: Rapid onset of action with over three times greater itch reduction versus placebo within 48 hours of the first dose and a four times greater improvement in sleep versus placebo as early as Day 4
Atopic dermatitis: Improvement of the clinical signs indicated by SCORAD components apparent at week 1 and increased through week 16

LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma today announced the presentation of new phase 2 data supporting the efficacy of its investigational monoclonal antibody, nemolizumab, at the virtual 30th EADV congress, taking place between 28 September and 2 October 2021.

Results from two key trials of nemolizumab given every 4 weeks, demonstrate rapid onset of action and significant reduction in symptoms for patients with prurigo nodularis (PN) and atopic dermatitis (AD), and new real-world evidence highlight the PN disease burden.